Access, interchangeability, litigation, and pricing dynamics for follow‑ons.
An article joins this feed when it matches these terms. Each one is also a search of its own.
BioPharm International Alvotech and Advanz Pharma announced October 14, 2026, the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL), which is marketed as Eylea HD in the United States.¹ Based on publicly available information, the…
Home / News / BioBlast® On 28 September 2026, Teva announced that it has strengthened its position in the biosimilars market with the FDA approval of its internally developed Degevma™ (denosumab-adet), biosimilar to Amgen’s Xgeva®. Degevma™ is indicated for all approved reference indications and…